

# **2025 INVESTOR** FACT SHEET

## ABOUT GENFLOW BIOSCIENCES

**Genflow** is pioneering groundbreaking gene therapies in partnership with leading organizations in longevity and gene delivery, aiming to slow the aging process and preempt age-related diseases. Our goal is not only to reduce healthcare costs, but to alleviate the profound emotional and societal burdens of a fast-growing aging demographic.

#### PROGRAMS

- MASH: IND-Enabling pre-clinical phase of experimental therapy on patients with MASH, formerly known as NASH, an age-related liver disease in early 2025;
- WERNER SYNDROME: Developing a therapy for Werner syndrome, a rare accelerated aging disease, by which SIRT6 messenger RNA delivers the gene to the skin;
- SARCOPENIA: Program to prevent age-related loss of muscle mass;
- Dogs: Clinical trial in aged dogs for prevention of age-related diseases and life extension; and
- 5. Ophthalmology: Cornea and glaucoma programs.

#### **RECENT NEWS**

**APR, '25** Genflow Signs MSA with Heureka Labs, Launching AI-Powered Partnership in Gene Therapy Research

**APR, '25** Genflow Launches New Ophthalmology Development Program, Signs MTA with Leading Ophthalmology Company


MAR, '25 Genflow Biosciences PLC Announces Institutional Investment

**FEB, '25** Genflow Biosciences Announces Advancements in SIRT6 Variant Patent Application

# LSE: GENF - OTCQB: GENFF



SIRT6 GENE: Epigenomic regulator gene that widely regulates aging; considered to be a potential therapeutic target for the treatment of diseases. Patented variant of SIRT6 found only in centenarians





## MANAGEMENT

### Tamara Joseph, Chair

Seasoned healthcare leader with extensive experience in both early-stage and commercial biotech companies.

### Dr. Eric Leire, MD, MBA, Founder/CEO

Involved in biotech for over 30 years, he has held senior positions including CEO of publicly traded biotech companies (Nasdaq, OTC.QB,OMX.Nasdaq).

# SCIENTIFIC ADVISORY BOARD

#### Dr. Vera Gorbunova, PhD

Co-Director, Rochester Aging Research Center; Affiliation: **Weizmann Inst. of Science** 

### Dr. Eric Verdin, MD/PhD

CEO & President, Buck Institute; Affiliation: *UCSF School Of Medicine* 

#### Dr. Matthew Hirschey, PhD

Ass't Prof, Duke Univ. School of Medicine; Affiliation: *American Heart Association* 

#### Dr. Manlio Vinciguerra, PhD

Princ. Investigator, University of Liverpool; Affiliation: **UCL** 

#### Prof. Dr. Sven Francque, PhD

MASH expert; *Univ. of Antwerp* 

Prof. Mary Rinella, MD

NASH expert; Univ. of Chicago Medicine

# GENFLOW BIOSCIENCES BIOPARK GOSSELIES

Rue Clément Ader, 10 B-6041 Charleroi Belgium

CONTACT

**2025 INVESTOR** 

FACT SHEET

Dr. Eric Leire info@genflowbio.com


### **HEADQUARTERS**

6 Heddon Street London W1B 4BT United Kingdom

## **INVESTOR RELATIONS**

Harbor Access, US

Jonathan Paterson +1 475 477 9401



SCAN For more information or visit GenflowBio.com

# LSE: GENF - OTCQB: GENFF